A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Primary Sponsor
Collaborating Groups
TROG Cancer Research
Accrual Target
412
Final Accrual
415
Closing Date of Accrual
20 August 2024
Trial Chairperson
Prof Sandro Porceddu - Princess Alexandra Hospital
Trial Contact
qa@trog.com.au
Related Post
11 June, 2025
Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer
LATEST NEWS: 11 JUNE 2025 New findings from a
10 June, 2025
MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer
LATEST NEWS: 10 JUNE 2025 A trial of a
